Approval · Notice of Compliance 37908 · 2026
MYLAN-VALACYCLOVIR: Notice of Compliance 37908
Issued July 13, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37908
- Date
- July 13, 2026
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYLAN-VALACYCLOVIR | Not yet assigned | — |
Medicinal ingredients
- VALACYCLOVIR HYDROCHLORIDE 500 MG per TAB
- VALACYCLOVIR HYDROCHLORIDE 1,000 MG per TAB